Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/17/2004 First Published: 4/23/2003


1.		Phase II/III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Versus Without Etoposide in Older Patients With Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				70 and over				Other				EORTC-20991 NCT00060385

Last Modified: 3/14/2008 First Published: 1/26/2003


2.		Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Prednisone Followed By Radiotherapy in Patients With Aggressive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 60				Other				DSHNHL-1999-2 EU-20242, NCT00053768

Last Modified: 5/19/2008 First Published: 6/23/2003


3.		Phase III Randomized Study of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)-Like Chemotherapy With Versus Without Rituximab in Patients With CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to 60				Other, Pharmaceutical / Industry				CAN-NCIC-LY9 ROCHE-CAN-NCIC-LY9, MINT-M39045, NCT00064116, LY9

Last Modified: 5/3/2007


4.		Phase I/II Study of R-Verapamil with EPOCH (VP-16/PRED/VCR/CTX/DOX), with Analysis of Drug Resistance Mechanisms, in Relapsed/Refractory Lymphomas and Pediatric Sarcomas and of EPOCH Alone in Previously Untreated HIV-Associated Lymphomas (Summary Last Modified 01/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				at least 1 year				NCI				NCI-90-C-0113E NCI-MB-255, NCI-T90-0047N, T90-0047

Last Modified: 5/1/1997


5.		Phase II Study of Sequential Anti-B4-bR and EPOCH for Refractory B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 05/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				physiologic 18 to 65				Other				DFCI-94025 NCI-V94-0582

Last Modified: 7/1/1997


6.		Phase II Randomized Pilot Study of EPOCH II (VP-16/DOX/VCR/PRED Alternating with CTX) Alone vs EPOCH II with IL-2 and PBSC in Lymphomas (Summary Last Modified 07/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 70				NCI				NCI-95-C-0073E NCI-T95-0068N, NCI-MB-356

Last Modified: 11/13/2007


7.		EPOCH Chemotherapy Plus Rituximab For Previously Treated Patients With AIDS-Associated Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-97-C-0040G NCI-T96-0036N, T96-0036, NCT00019253

Last Modified: 7/1/2002 First Published: 7/1/2000


8.		Phase II Study of Doxorubicin, Etoposide, Vincristine, Cyclophosphamide, and Prednisone (EPOCH) in Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (Summary Last Modified 07/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Not specified				NCI				CLB-C59910 NCT00005964

Last Modified: 5/1/2001 First Published: 12/1/2000


9.		Phase II Study of Rituximab Followed By Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisone (EPOCH) in Patients With Refractory or Recurrent CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				WHC-99365 NCI-V00-1630, NCT00006669

Last Modified: 8/7/2008 First Published: 7/1/2002


10.		Phase II Study of Induction Therapy Comprising Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) and Maintenance Therapy Comprising Lamivudine, Zidovudine, and Interferon alfa in Patients With HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				AMC-033 NCT00041327

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute